TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TFF Pharmaceuticals Inc (NASDAQ: TFFP) has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for defensive research into countermeasures against biological warfare. Under the terms of the.

TFF Pharma Inks Research Pact With US Army For Dry Powder Medical Countermeasures

New collaboration to study the use of Thin Film Freezing technology to formulate dry powder recombinant vaccine against SARS-CoV-2 for pulmonary delivery New collaboration to study the use of Thin Film Freezing technology to formulate dry powder recombinant vaccine against SARS-CoV-2 for pulmonary delivery

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures

AUSTIN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in a fireside chat at the 34th Annual Roth Conference in Dana Point, California March 13 - 15, 2022. Company management will also be participating in one-on-one meetings throughout the conference.

TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference

Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET

TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022

AUSTIN, Texas and SOMERSET, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) and Catalent today announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF Pharmaceuticals' patented Thin Film Freezing (TFF) technology. Under the agreement, Catalent will provide its scale-up expertise and manufacturing capabilities to TFF Pharmaceuticals as its preferred development and manufacturing partner, and Catalent will be able to offer its customers access to the innovative TFF technology, which has the potential to increase the adoption of the pulmonary route for the systemic delivery of biotherapeutics.

TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

Preclinical studies show that TFF Pharmaceuticals Inc's (NASDAQ: TFFP) inhaled niclosamide product candidate inhibits viral replication of both the Delta and Omicron variants of SARS-CoV-2. More specifically, nirmatrelvir and molnupiravir showed complete inhibition of the.

TFF Pharma's Inhaled Niclosamide Shows Potent Activity Against Omicron Variant

Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

Complete Safety Data Anticipated by End of 1Q 2022

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19

By StoryTrading Pfizer collaboration just revealed in presentation update - no PR issued yet!

Recently Revealed Pfizer Collaboration Might Just Be What The Doctor Ordered For TFF Pharmaceuticals

Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate Asthma

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will host a science day related to two of the company's lead assets, inhaled voriconazole for invasive pulmonary aspergillosis (IPA) and inhaled AUG-3387 for COVID-19, on Monday, December 13, 2021 from 1:30pm – 3:00pm Eastern Time.

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

After a long and painful downside, TFFP's stock has finally delivered a one-day outperformance with respect to the big Covid plays due to the Omicron variant. The next question is whether this is just another blip as was the case in July when there were positive clinical trials results for Augmenta's drug candidate using TFF (Thin Film Freezing) delivery.

TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q3 2021 Results - Earnings Call Transcript

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -142.86% and -97.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

TFF Pharmaceuticals, Inc. (TFFP) Reports Q3 Loss, Lags Revenue Estimates

Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs; Both Programs Advancing into Phase 2 Testing

TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients

AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will present a corporate overview at the 12th Annual Jefferies London Healthcare Conference taking place November 16-19, 2021.

TFF Pharmaceuticals to Participate in the 12th Annual Jefferies London Healthcare Conference 2021

TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021

First Patient in Phase 1 Trial to be Dosed in November with Enrollment Completion Anticipated by Early Q1 2022

TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19

Results published in bioRxiv Show That Delivery of Dry Powder AUG-3387 Following Viral Inoculation Led to Dose-Dependent Reduction in Lung Viral Load in Hamsters

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load

TFF Pharmaceuticals Inc (NASDAQ: TFFP) has announced topline results from Phase 1 trial for Tacrolimus Inhalation Powder. Data showed a good safety profile and demonstrating that therapeutic drug levels can be achieved at low doses.

TFF Pharma's Inhaled Tacrolimus Powder Moves Closer To Phase 2 In Lung Transplantation

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will present a corporate overview at 23rd H.C. Wainwright Annual Global Investment Conference being held from September 13-15th, 2021.

TFF Pharmaceuticals to Present at 23rd H.C. Wainwright Annual Global Investment Conference

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q2 2021 Results - Earnings Call Transcript

Additional Data Readouts and Initiation of Pivotal Trials for Inhaled Tacrolimus and Voriconazole Programs Expected in 2H 2021

TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

Augmenta Bioworks and TFF Pharmaceuticals Inc (NASDAQ: TFFP) have announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2).  The companies have selected a final formulation of AUG-3387 that will be used to complete in vivo preclinical efficacy studies in the coming weeks and will proceed with toxicology studies by the end of 2021.

News for TFF Pharmaceuticals Stock (TFFP)